The New IASLC-ATS-ERS Lung Adenocarcinoma Classification: What the Surgeon Should Know

Seminars in Thoracic and Cardiovascular Surgery

Volumn 26, Issue 3, 2014, Pages 210-222

  Eguchi, Takashi ^a,b   Kadota, Kyuichi ^a,c   Park, Bernard J ^a   Travis, William D ^a   Jones, David R ^a   Adusumilli, Prasad S ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b SHINSHU UNIVERSITY   (Japan)

^c KAGAWA UNIVERSITY   (Japan)

Author keywords

Histologic classification; Limited resection; Lung adenocarcinoma; Micropapillary; Small lung nodules

Indexed keywords

ADENOCARCINOMA IN SITU; ARTICLE; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; GENE MUTATION; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; INTRAOPERATIVE PERIOD; LUNG ADENOCARCINOMA; LUNG RESECTION; MEDICAL SOCIETY; OUTCOME ASSESSMENT; PATIENT MONITORING; POSTOPERATIVE PERIOD; PRACTICE GUIDELINE; PREOPERATIVE EVALUATION; PROFESSIONAL KNOWLEDGE; RECURRENCE RISK; SURGEON; TREATMENT INDICATION; TUMOR INVASION; VALIDATION STUDY; ADENOCARCINOMA; BIOPSY; CLASSIFICATION; GENETICS; LUNG NEOPLASMS; MUTATION; NOMENCLATURE; PATHOLOGY; PREDICTIVE VALUE; REPRODUCIBILITY; RISK ASSESSMENT; RISK FACTOR; STAINING; TIME; TREATMENT OUTCOME; TUMOR RECURRENCE;

TUMOR MARKER;

ADENOCARCINOMA; BIOMARKERS, TUMOR; BIOPSY; HUMANS; LUNG NEOPLASMS; MUTATION; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PNEUMONECTOMY; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; RISK FACTORS; STAINING AND LABELING; TERMINOLOGY AS TOPIC; TIME FACTORS; TREATMENT OUTCOME;

EID: 84927934681     PISSN: 10430679     EISSN: 15329488     Source Type: Journal    
DOI: 10.1053/j.semtcvs.2014.09.002     Document Type: Article

References (60)

1. Travis W.D., Brambilla E., Noguchi M., et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011, 6:244-285.
2. Edge S.B., Compton C.C. The American Joint Committee on Cancer: The 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 2010, 17:1471-1474.
3. Yoshizawa A., Motoi N., Riely G.J., et al. Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: Prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. Mod Pathol 2011, 24:653-664.
4. Russell P.A., Wainer Z., Wright G.M., et al. Does lung adenocarcinoma subtype predict patient survival?: A clinicopathologic study based on the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary lung adenocarcinoma classification. J Thorac Oncol 2011, 6:1496-1504.
5. Gu J., Lu C., Guo J., et al. Prognostic significance of the IASLC/ATS/ERS classification in Chinese patients-A single institution retrospective study of 292 lung adenocarcinoma. J Surg Oncol 2013, 107:474-480.
6. Warth A., Muley T., Meister M., et al. The novel histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification system of lung adenocarcinoma is a stage-independent predictor of survival. J Clin Oncol 2012, 30:1438-1446.
7. Yeh Y.C., Wu Y.C., Chen C.Y., et al. Stromal invasion and micropapillary pattern in 212 consecutive surgically resected stage I lung adenocarcinomas: Histopathological categories for prognosis prediction. J Clin Pathol 2012, 65:910-918.
8. Woo T., Okudela K., Mitsui H., et al. Prognostic value of the IASLC/ATS/ERS classification of lung adenocarcinoma in stage I disease of Japanese cases. Pathol Int 2012, 62:785-791.
9. Tsuta K., Kawago M., Inoue E., et al. The utility of the proposed IASLC/ATS/ERS lung adenocarcinoma subtypes for disease prognosis and correlation of driver gene alterations. Lung Cancer 2013, 81:371-376.
10. Yoshizawa A., Sumiyoshi S., Sonobe M., et al. Validation of the IASLC/ATS/ERS lung adenocarcinoma classification for prognosis and association with EGFR and KRAS gene mutations: Analysis of 440 Japanese patients. J Thorac Oncol 2013, 8:52-61.
11. Hung J.J., Jeng W.J., Chou T.Y., et al. Prognostic value of the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society lung adenocarcinoma classification on death and recurrence in completely resected stage I lung adenocarcinoma. Ann Surg 2013, 258:1079-1086.
12. Song Z., Zhu H., Guo Z., et al. Prognostic value of the IASLC/ATS/ERS classification in stage I lung adenocarcinoma patients-Based on a hospital study in China. Eur J Surg Oncol 2013, 39:1262-1268.
13. Urer H.N., Kocaturk C.I., Gunluoglu M.Z., et al. Relationship between lung adenocarcinoma histological subtype and patient prognosis. Ann Thorac Cardiovasc Surg 2014, 20:12-18.
14. Yanagawa N., Shiono S., Abiko M., et al. New IASLC/ATS/ERS classification and invasive tumor size are predictive of disease recurrence in stage I lung adenocarcinoma. J Thorac Oncol 2013, 8:612-618.
15. Zhang J., Wu J., Tan Q., et al. Why do pathological stage IA lung adenocarcinomas vary from prognosis?: A clinicopathologic study of 176 patients with pathological stage IA lung adenocarcinoma based on the IASLC/ATS/ERS classification. J Thorac Oncol 2013, 8:1196-1202.
16. Westaway D.D., Toon C.W., Farzin M., et al. The International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society grading system has limited prognostic significance in advanced resected pulmonary adenocarcinoma. Pathology 2013, 45:553-558.
17. Hung J.J., Yeh Y.C., Jeng W.J., et al. Predictive value of the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification of lung adenocarcinoma in tumor recurrence and patient survival. J Clin Oncol 2014, 32(22):2357-2364.
18. Cha M.J., Lee H.Y., Lee K.S., et al. Micropapillary and solid subtypes of invasive lung adenocarcinoma: Clinical predictors of histopathology and outcome. J Thorac Cardiovasc Surg 2014, 147:921-928. [e2].
19. Yanagawa N., Shiono S., Abiko M., et al. The correlation of the International Association for the Study of Lung Cancer (IASLC)/American Thoracic Society (ATS)/European Respiratory Society (ERS) classification with prognosis and EGFR mutation in lung adenocarcinoma. Ann Thorac Surg 2014, 98(2):453-458.
20. Mansuet-Lupo A., Bobbio A., Blons H., et al. The new histological classification of lung primary adenocarcinoma subtypes is a reliable prognostic marker and identifies tumors with different mutation status: The experience of a French cohort. Chest 2014, 146(3):633-643.
21. Ito M., Miyata Y., Kushitani K., et al. Prediction for prognosis of resected pT1a-1bN0M0 adenocarcinoma based on tumor size and histological status: Relationship of TNM and IASLC/ATS/ERS classifications. Lung Cancer 2014, 85:270-275.
22. Thunnissen E., Beasley M.B., Borczuk A.C., et al. Reproducibility of histopathological subtypes and invasion in pulmonary adenocarcinoma. An international interobserver study. Mod Pathol 2012, 25:1574-1583.
23. Zhang Y., Sun Y., Pan Y., et al. Frequency of driver mutations in lung adenocarcinoma from female never-smokers varies with histologic subtypes and age at diagnosis. Clin Cancer Res 2012, 18:1947-1953.
24. Villa C., Cagle P.T., Johnson M., et al. Correlation of EGFR mutation status with predominant histologic subtype of adenocarcinoma according to the new lung adenocarcinoma classification of the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society. Arch Pathol Lab Med 2014.
25. Rekhtman N., Ang D.C., Riely G.J., et al. KRAS mutations are associated with solid growth pattern and tumor-infiltrating leukocytes in lung adenocarcinoma. Mod Pathol 2013, 26:1307-1319.
26. Song Z., Zhu H., Guo Z., et al. Correlation of EGFR mutation and predominant histologic subtype according to the new lung adenocarcinoma classification in Chinese patients. Med Oncol 2013, 30:645.
27. Kadota K., Yeh Y.C., D'Angelo S.P., et al. Associations between mutations and histologic patterns of mucin in lung adenocarcinoma: Invasive mucinous pattern and extracellular mucin are associated with KRAS mutation. Am J Surg Pathol 2014, 38:1118-1127.
28. Sun Y., Yu X., Shi X., et al. Correlation of survival and EGFR mutation with predominant histologic subtype according to the new lung adenocarcinoma classification in stage IB patients. World J Surg Oncol 2014, 12:148.
29. Fernandez-Cuesta L., Plenker D., Osada H., et al. CD74-NRG1 fusions in lung adenocarcinoma. Cancer Discov 2014, 4:415-422.
30. Suzuki K., Koike T., Asakawa T., et al. A prospective radiological study of thin-section computed tomography to predict pathological noninvasiveness in peripheral clinical IA lung cancer (Japan Clinical Oncology Group 0201). J Thorac Oncol 2011, 6:751-756.
31. Shimada Y., Yoshida J., Hishida T., et al. Predictive factors of pathologically proven noninvasive tumor characteristics in T1aN0M0 peripheral non-small cell lung cancer. Chest 2012, 141:1003-1009.
32. max stratify the risk of recurrence in patients undergoing limited resection for lung adenocarcinoma
33. Takahashi M., Shigematsu Y., Ohta M., et al. Tumor invasiveness as defined by the newly proposed IASLC/ATS/ERS classification has prognostic significance for pathologic stage IA lung adenocarcinoma and can be predicted by radiologic parameters. J Thorac Cardiovasc Surg 2014, 147:54-59.
34. Rekhtman N., Brandt S.M., Sigel C.S., et al. Suitability of thoracic cytology for new therapeutic paradigms in non-small cell lung carcinoma: High accuracy of tumor subtyping and feasibility of EGFR and KRAS molecular testing. J Thorac Oncol 2011, 6:451-458.
35. Rodriguez E.F., Monaco S.E., Dacic S. Cytologic subtyping of lung adenocarcinoma by using the proposed International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society (IASLC/ATS/ERS) adenocarcinoma classification. Cancer Cytopathol 2013, 121:629-637.
36. Ferretti G.R., Busser B., de Fraipont F., et al. Adequacy of CT-guided biopsies with histomolecular subtyping of pulmonary adenocarcinomas: Influence of ATS/ERS/IASLC guidelines. Lung Cancer 2013, 82:69-75.
37. Yoshida J., Nagai K., Yokose T., et al. Limited resection trial for pulmonary ground-glass opacity nodules: Fifty-case experience. J Thorac Cardiovasc Surg 2005, 129:991-996.
38. Yeh Y.C., Nitadori J.I., Kadota K., et al. Using frozen section to identify histologic patterns in stage I lung adenocarcinoma
39. Blasberg J.D., Pass H.I., Donington J.S. Sublobar resection: A movement from the Lung Cancer Study Group. J Thorac Oncol 2010, 5:1583-1593.
40. Yoshida J., Ishii G., Yokose T., et al. Possible delayed cut-end recurrence after limited resection for ground-glass opacity adenocarcinoma, intraoperatively diagnosed as Noguchi type B, in three patients. J Thorac Oncol 2010, 5:546-550.
41. Landreneau R.J., Normolle D.P., Christie N.A., et al. Recurrence and survival outcomes after anatomic segmentectomy versus lobectomy for clinical stage I non-small-cell lung cancer: A propensity-matched analysis. J Clin Oncol 2014, 32(23):2449-2455.
42. Sica G., Yoshizawa A., Sima C.S., et al. A grading system of lung adenocarcinomas based on histologic pattern is predictive of disease recurrence in stage I tumors. Am J Surg Pathol 2010, 34:1155-1162.
43. Zhang Y., Sun Y., Shen L., et al. Predictive factors of lymph node status in small peripheral non-small cell lung cancers: Tumor histology is more reliable. Ann Surg Oncol 2013, 20:1949-1954.
44. Yeh Y.C., Nitadori J., Kadota K., et al. Micropapillary histology is associated with occult lymph node metastasis (pN2) in patients with clinically N2-negative (cN0/N1) lung adenocarcinoma. J Thorac Oncol 2013, 8:S671.
45. Tsutani Y., Miyata Y., Nakayama H., et al. Sublobar resection for lung adenocarcinoma meeting node-negative criteria on preoperative imaging. Ann Thorac Surg 2014, 97:1701-1707.
46. Nitadori J., Bograd A.J., Kadota K., et al. Impact of micropapillary histologic subtype in selecting limited resection vs lobectomy for lung adenocarcinoma of 2cm or smaller. J Natl Cancer Inst 2013, 105:1212-1220.
47. Kadota K., Villena-Vargas J., Yoshizawa A., et al. Prognostic significance of adenocarcinoma in situ, minimally invasive adenocarcinoma, and nonmucinous lepidic predominant invasive adenocarcinoma of the lung in patients with stage I disease. Am J Surg Pathol 2014, 38:448-460.
48. Yokose T., Suzuki K., Nagai K., et al. Favorable and unfavorable morphological prognostic factors in peripheral adenocarcinoma of the lung 3cm or less in diameter. Lung Cancer 2000, 29:179-188.
49. Miyoshi T., Satoh Y., Okumura S., et al. Early-stage lung adenocarcinomas with a micropapillary pattern, a distinct pathologic marker for a significantly poor prognosis. Am J Surg Pathol 2003, 27:101-109.
50. Makimoto Y., Nabeshima K., Iwasaki H., et al. Micropapillary pattern: A distinct pathological marker to subclassify tumours with a significantly poor prognosis within small peripheral lung adenocarcinoma (
51. Kamiya K., Hayashi Y., Douguchi J., et al. Histopathological features and prognostic significance of the micropapillary pattern in lung adenocarcinoma. Mod Pathol 2008, 21:992-1001.
52. Sanchez-Mora N., Presmanes M.C., Monroy V., et al. Micropapillary lung adenocarcinoma: A distinctive histologic subtype with prognostic significance. Case series. Hum Pathol 2008, 39:324-330.
53. Nagano T., Ishii G., Nagai K., et al. Structural and biological properties of a papillary component generating a micropapillary component in lung adenocarcinoma. Lung Cancer 2010, 67:282-289.
54. Sumiyoshi S., Yoshizawa A., Sonobe M., et al. Pulmonary adenocarcinomas with micropapillary component significantly correlate with recurrence, but can be well controlled with EGFR tyrosine kinase inhibitors in the early stages. Lung Cancer 2013, 81:53-59.
55. Ujiie H., Buitrago D., Kadota K., et al. Sites, symptoms, CT scan findings and survival in patients with recurrence after curative-intent surgical resection for stage I lung adenocarcinoma. J Thorac Oncol 2013, 8:S164.
56. Kadota K., Suzuki K., Kachala S.S., et al. A grading system combining architectural features and mitotic count predicts recurrence in stage I lung adenocarcinoma. Mod Pathol 2012, 25:1117-1127.
57. Kadota K., Yeh Y.C., Sima C.S., et al. The cribriform pattern identifies a subset of acinar predominant tumors with poor prognosis in patients with stage I lung adenocarcinoma: A conceptual proposal to classify cribriform predominant tumors as a distinct histologic subtype. Mod Pathol 2014, 27:690-700.
58. Kadota K., Nitadori J., Sarkaria I.S., et al. Thyroid transcription factor-1 expression is an independent predictor of recurrence and correlates with the IASLC/ATS/ERS histologic classification in patients with stage I lung adenocarcinoma. Cancer 2013, 119:931-938.
59. Suzuki K., Kadota K., Sima C.S., et al. Clinical impact of immune microenvironment in stage I lung adenocarcinoma: Tumor interleukin-12 receptor beta2 (IL-12Rbeta2), IL-7R, and stromal FoxP3/CD3 ratio are independent predictors of recurrence. J Clin Oncol 2013, 31:490-498.
60. Nitadori J., Kadota K., Sima C.S., et al. Spread through alveolar spaces (STAS): A newly recognized pattern of invasion in lung adenocarcinoma associated with increased recurrence in patients undergoing limited resection for ≤2cm tumors. J Thorac Oncol 2013, 8:S955.